Phase II trial of bevacizumab (A), lenalidomide (R), docetaxel (D), and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

@article{Huang2011PhaseIT,
  title={Phase II trial of bevacizumab (A), lenalidomide (R), docetaxel (D), and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).},
  author={Xuan Huang and Yangmin M. Ning and Marcia Mulquin and Rohit Madan and James L. Gulley and Paul Gustav Kluetz and David E. Adelberg and Phil M. Arlen and Lori M. Minasian and Bamidele A. Adesunloye and Seth M Steinberg and John Joseph Wright and Jane B. Trepel and Chi Jen Chen and Carol W. Bassim and Andrea B. Apolo and William Douglas Figg and William L. Dahut},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2011},
  volume={29 15_suppl},
  pages={4574}
}
4574 Background: Angiogenesis may play a critical role in the progression of mCRPC. Previously we have shown the potent anti-tumor activity of the combination of D, Thalidomide (T), A, and P in mCRPC (Ning JCO 2010). We hypothesized that combining R, an analogue of T, with A, D and P would have a more favorable efficacy/toxicity profile. METHODS All pts had chemotherapy-naïve progressive mCRPC. 6 pts were treated with R at 15 and 20 mg prior to doses at 25 mg. Treatment is 75 mg/m2 D, 15 mg… CONTINUE READING